Kei Sato was looking for his next big challenge five years ago when it smacked him — and the world — in the face. The ...

Five years after COVID-19 reached pandemic status, public health experts reflect on what we learned—and how those lessons can ...

This article will appear in the forthcoming Spring 2025 issue of Johns Hopkins MagazineFrom afar, the images look like ...

Because SARS‑CoV‑2 was a new virus, human bodies had not developed an antibody ... shots or other therapies yet to be developed—will be needed throughout your life. Pfizer's vaccine, also known as ...

It is important to understand the correlates of protection against SARS-CoV-2 and its variants for future vaccine design. Here, the authors show that the complement system enhances the antibody ...

A slow immune response to SARS-CoV-2 infection, delayed viral clearance, and viral rebound can all increase a person’s risk ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

Concurrent analysis of whole-genome DNA methylation and single-cell RNA sequencing data from COVID-19 patients and controls ...

Between April 2020 and December 2022, over 535,000 people in Germany downloaded and activated the Corona Data Donation App ...

Imagine a previously unknown bug—new to our immune defenses—that suddenly emerged and rapidly spread all over the globe, ...

SARS-CoV-2 has been evolving the ability to evade the immune system about twice as fast as the fastest-evolving flu virus. It averages more than a dozen significant changes every year.

This mechanism links TGFβ release in SARS-CoV-2 infection to multisystem inflammatory syndrome in children, and could inform the development of therapies for managing this serious condition.